An Israeli-developed drug for the treatment of multiple sclerosis won approval for sale in the United States. REBIF, or Interferon Beta, developed at the Weizmann Institute of Science, delays relapses of the degenerative disease. The drug has been in use in Europe since 1996, and is available in more than 70 countries worldwide.
As the Year Turns, Support the Journalism You Trust. JTA covers the stories shaping Jewish life around the world — with the depth this moment calls for. As you reflect on the year ahead, consider a gift that keeps independent Jewish journalism strong.
The Archive of the Jewish Telegraphic Agency includes articles published from 1923 to 2008. Archive stories reflect the journalistic standards and practices of the time they were published.
